EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Tezepelumab in “United Airway Disease” (Asthma and CRSwNP)

Chiara Lupia, Giovanna Lucia Piazzetta, Daniela Pastore, Nadia Lobello, Mariaimmacolata Preianò, Emanuela Chiarella iD, Angelantonio Maglio, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia iD

Case Reports in Pulmonology · 2026-01 · 2026 (1)

DOI: 10.1155/crpu/6616379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Pulmonology, online erschienen am 03.03.2026. Verfasst von Chiara Lupia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, "Magna Græcia" University, Catanzaro, Italy, unicz.it. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe asthma is a heterogeneous disease typically characterized by inadequate symptom control, even with frequent oral corticosteroids, large doses of inhaled corticosteroids, and long‐acting β 2 ‐adrenergic agonists. The latest Global Initiative for Asthma (GINA) recommendations suggest adding biological therapies at Step 5 to optimize standard treatments. Although there is a wide range of therapeutic options for T2‐high asthma, unfortunately, for T2‐low asthma, we still have limited therapeutic choices. Our case report refers to a 64‐year‐old woman with severe T2‐low asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) who had already tested other standard therapies without clinical or functional benefits. She is being treated with tezepelumab (210 mg subcutaneous injection, administered every 4 weeks), an antithymic stromal lymphopoietin (TSLP) human monoclonal antibody. After the third dose, she showed significant clinical and functional benefits, which were also confirmed after 6 months of add‐on biological therapy with anti‐TSLP. In conclusion, this case study suggests that tezepelumab can provide rapid and effective therapeutic action in patients with severe T2‐low asthma and nasal polyposis.

Schlagwörter

Stichwörter der Autor:innen

T2-lowTSLPnasal polypssevere asthmatezepelumab

Autor:innen und Institutionen

  • Department of Health Sciences, "Magna Græcia" University, Catanzaro, Italy, unicz.it.
  • Department of Medical and Surgical Sciences, "Magna Græcia" University, Catanzaro, Italy, unicz.it.
  • Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy, unisa.it.

ORCID-Profile: Emanuela Chiarella, Corrado Pelaia

Zitieren

APA

Lupia, C., Piazzetta, G. L., Pastore, D., Lobello, N., Preianò, M., Chiarella, E., Maglio, A., Vatrella, A., Pelaia, G., & Pelaia, C. (2026). Effects of Tezepelumab in “United Airway Disease” (Asthma and CRSwNP). Case Reports in Pulmonology, 2026(1). https://doi.org/10.1155/crpu/6616379

Vancouver

Lupia C, Piazzetta GL, Pastore D, Lobello N, Preianò M, Chiarella E, et al. Effects of Tezepelumab in “United Airway Disease” (Asthma and CRSwNP). Case Reports in Pulmonology. 2026;2026(1). doi:10.1155/crpu/6616379

BibTeX
@article{Lupia2026,
  author = {Lupia, Chiara and Piazzetta, Giovanna Lucia and Pastore, Daniela and Lobello, Nadia and Preianò, Mariaimmacolata and Chiarella, Emanuela and Maglio, Angelantonio and Vatrella, Alessandro and Pelaia, Girolamo and Pelaia, Corrado},
  title = {Effects of Tezepelumab in “United Airway Disease” (Asthma and CRSwNP)},
  journal = {Case Reports in Pulmonology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crpu/6616379}
}
Kostenlos starten →